ALFA Filings
Every announcement, straight from the exchange
Every Lupin merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Lupin Limited's step-down subsidiary, Multicare Pharmaceuticals Philippines, Inc., completed a buyback of 30,559 shares. MPPI is now a wholly owned step-down subsidiary of the Company.
Lupin Inc. licensed two oncology programs to Kaveri Therapeutics in exchange for an 82.2% stake, valued at ₹15.36 Crore.
Lupin's subsidiary Nanomi completed the acquisition of shares in MPPI. This increases Nanomi's effective shareholding in MPPI to 99.89%.
Lupin Limited incorporated a wholly owned subsidiary, Lupin (Thailand) Limited, on April 17, 2026. The new entity, based in Thailand, will focus on importing, marketing, and distributing pharmaceutical products. It has an initial paid-up capital of 3,000,000 Baht, entirely held by the parent company.